Regencell Bioscience Holdings Ltd. (Hong Kong SAR, China)

The Company is a bioscience company that focuses on the research, development, and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).
The Company s goal is to save and improve the lives of ADHD, ASD, and COVID patients, their families, and caregivers and become a market leader for the best natural and holistic treatment globally. The TCM Practitioner has been treating ADHD and ASD patients for over 30 years, more recently, infectious diseases affecting people's immune system such as COVID-19. The Company intends to commercialize the TCM formulae utilized in his treatment first in Hong Kong and subsequently globalize the use of such TCM formulae in order to address the unmet medical needs of the growing ADHD, ASD, and COVID patient population in other countries such as the U.S.
The Company is in the research and development stage and has not yet generated any revenue since inception.
HISTORY
2014 The Company was incorporated on October 30, 2014, under the laws of the Cayman Islands under the name Regencell Bioscience Holdings Limited .
2021 The Company listed its Ordinary Shares on the Nasdaq Capital Market under the symbol “RGC” on July 16, 2021.